Pastan Ira, Hassan Raffit, FitzGerald David J, Kreitman Robert J
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Annu Rev Med. 2007;58:221-37. doi: 10.1146/annurev.med.58.070605.115320.
Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.
免疫毒素是用于治疗癌症的蛋白质,由与毒素相连的抗体片段组成。免疫毒素与癌细胞表面抗原结合,通过内吞作用进入细胞并将其杀死。最有效的免疫毒素由细菌和植物毒素制成。经过多年改进已产生重组免疫毒素;这些治疗性蛋白质是利用蛋白质工程制造的。单个免疫毒素旨在治疗特定癌症。迄今为止,在治疗血液肿瘤方面已取得最大成功。成功治疗实体瘤的障碍包括难以渗透到肿瘤块中以及对免疫毒素毒素成分的免疫反应,这限制了可给予的疗程数量。正在寻求克服这些限制的策略。